What Are Senolytics? The Science, the Protocols, and What Actually Matters

Co-authored by Vittorio Sebastiano, PhD. Professor of Biological Chemistry, UC Irvine, and Adjunct Professor at Stanford University School of Medicine. Pioneer of Epigenetic Reprogramming of Aging (ERA), with 50+ publications in Nature, Science, and Cell.

Senolytics are compounds being studied for their potential to support the body's management of senescent cells, the aging cells (popularly called "zombie cells") that stop dividing but keep emitting inflammatory signals. Research suggests senolytics work through a "hit-and-run" mechanism: concentrated, intermittent dosing rather than daily chronic use. Most human data is limited, but the science points toward timing and protocol design mattering as much as the compounds themselves.

Why Senescent Cells Matter in Aging

Senescent cells are a hallmark of biological aging. As you age, cells accumulate damage and lose their ability to divide. Rather than dying off, many cells enter a state called senescence, they stop replicating but remain metabolically active, secreting inflammatory molecules collectively called the senescence-associated secretory phenotype, or SASP. This half-alive, half-dead state is why they are often nicknamed "zombie cells."

Vittorio Sebastiano, PhD, Professor, Biological Chemistry, UC Irvine.

Senescent cells are not just dormant, they are active sources of chronic inflammation. Their secretory profile disrupts the tissue microenvironment and accelerates aging in neighboring cells. This creates a cascade problem. A handful of senescent cells triggers inflammation in surrounding healthy tissue. That inflammation drives more cells to become senescent. Over decades, senescent cell burden increases in your joints, blood vessels, organs, and immune system. Evidence suggests their accumulation contributes to age-related conditions from arthritis to cardiovascular dysfunction to weakened immunity.

The body does attempt to clear senescent cells naturally through immune-mediated mechanisms and programmed cell death. But clearance becomes less efficient with age. This imbalance, more accumulation and less clearance, is what aging researchers are now targeting.

Expert Perspective: Vittorio Sebastiano, PhD

Senescent cells sit where aging biology and regenerative medicine meet. My work on epigenetic reprogramming shows that cellular aging isn't simply unidirectional, senescence can be targeted and reversed through strategies that engage the cell's own renewal machinery. Senolytics represent a pragmatic window into that mechanism: by supporting the removal of dysfunctional senescent cells, we reduce the inflammatory burden that accelerates tissue aging and open space for cellular regeneration. The evidence suggests that strategic, intermittent clearance approaches align more closely with how aging biology actually works than continuous suppression strategies.

What Senolytic Compounds Are and How They Work

Senolytics are compounds identified through research to selectively trigger death in senescent cells while leaving healthy cells relatively unharmed. The prefix "senolytic" literally means "senescent-cell-breaking." Unlike therapies that prevent senescence or slow its development, senolytics are designed to directly support the body's cellular maintenance processes.

The most studied natural senolytics are flavonoids, plant compounds with antioxidant and anti-inflammatory properties. Fisetin, a flavonoid found in strawberries and other fruits and vegetables, has emerged from preclinical research as one of the most promising candidates. Other compounds being studied include quercetin (an antioxidant sourced from Japanese pagoda bud), dasatinib plus quercetin combinations (a drug paired with a natural compound), and various polyphenols.

Research suggests senolytics work by triggering apoptosis, programmed cell death, specifically in cells displaying senescent markers. The mechanism varies by compound but often involves pathways like p53 activation, anti-apoptotic protein inhibition (such as BCL-2 and BCL-xL), or metabolic stress signaling.

The Protocol Question: Why Timing Matters More Than You'd Think

Here's where senolytic science becomes unexpectedly practical: the compounds appear to work best when dosed intermittently, not continuously.

This insight comes from preclinical research showing senolytics operate through what researchers call a "hit-and-run" mechanism. The idea is direct: senolytics trigger senescent cell death acutely. Once senescent cells are cleared, continued dosing provides no additional benefit, the target population is already reduced. Chronic daily dosing may create unnecessary drug burden without additional cellular benefit and could theoretically trigger adaptation or tolerance.

Foundational evidence: Yousefzadeh et al. (2018), published in EBioMedicine, found that intermittent fisetin dosing in aged mice reduced senescence markers across multiple tissues and extended health and lifespan, consistent with this hit-and-run model.

More recent preclinical work strengthened the concept. Intermittent fisetin improved arterial function in old mice by lowering vascular cell senescence and SASP-related inflammation (Mahoney et al., Aging Cell 2024). In aging skeletal muscle, intermittent fisetin improved physical function and reduced senescence markers, with effects comparable to genetic clearance of senescent cells and to a synthetic senolytic drug (Murray et al., Aging Cell 2025). That benchmark matters, because genetically deleting senescent cells is the gold-standard proof in this field, and a natural flavonoid coming close to it is a strong signal.

This represents a key distinction from most supplement protocols, which assume daily dosing optimizes benefit. With senolytics, research suggests the opposite: concentrated dosing spaced strategically (monthly, or every 4 to 8 weeks) may be more effective than spreading the same dose daily.

The Human Data Reality: What We Know and Don't Know

Senolytic research in humans is early. This is the most important context for anyone evaluating senolytic supplements.

Institutional trials represent the leading edge. Mayo Clinic's AFFIRM trial (NCT03430037) studies fisetin for frailty and inflammation in older women. The COVID-FIS pilot (NCT04537299) tested fisetin in older adults during COVID-19. The STOP-Sepsis trial (NCT05758246) is enrolling 220 elderly patients testing fisetin at 20mg/kg (roughly 1400mg for a 70kg person), given as a single dose or two doses spaced one day apart, for sepsis progression. A separate vascular function trial at the University of Colorado Boulder (NCT06133634) is ongoing, with results not yet public.

One human result stands out, though it used a different compound. In a 9-person open-label pilot in patients with diabetic kidney disease, three days of dasatinib (100mg/day) plus quercetin (1000mg/day) reduced senescent-cell burden in fat tissue within 11 days, shown by drops in p16 and p21 markers and in senescence-associated beta-galactosidase activity (Hickson et al., EBioMedicine 2019). It was the first direct evidence that senolytics clear senescent cells in people, and an earlier first-in-human pilot in pulmonary fibrosis found the same combination improved walking endurance and physical function (Justice et al., EBioMedicine 2019). The caveat is important: this was dasatinib, a prescription drug, paired with quercetin, not fisetin, in a small and disease-specific group. It validates the mechanism in humans without proving fisetin specifically or any aging outcome.

The bottom line: there are no Phase 3 human trials establishing senolytic efficacy in aging populations. The human evidence base is preclinical research and small early-stage trials. Language like "supports the body's natural cellular maintenance processes" reflects this evidence reality. It's mechanistically grounded but not yet proven in large human populations.

What the Research Shows: Evidence by Protocol Type

The intermittent, pulse-style dosing concept has stronger research support than chronic daily senolytic dosing. This distinction matters for evaluating supplement protocols.

Intermittent / pulse approach. Preclinical evidence: moderate to strong. Yousefzadeh et al. (2018) established the foundational hit-and-run mechanism in mice. More recent studies confirmed that intermittent fisetin produced measurable senescence reduction with recovery periods between doses, across vascular, skeletal muscle, and immune tissues.

Practical translation: Mayo Clinic researchers use approximately 20mg/kg (roughly 1400mg for a 70kg adult) dosed for 2 consecutive days, repeated every 1 to 2 months. This is the closest human-applicable reference protocol from institutional research.

Chronic daily low-dose approach. Preclinical evidence: limited. No published studies specifically support continuous daily low-dose senolytic efficacy. If senolytics work via hit-and-run clearance, continuous daily dosing would clear the available senescent cells once, then offer no additional benefit until new cells accumulate. There is also a theoretical concern that continuous exposure might trigger adaptation or tolerance over time.

If you're evaluating senolytic supplement protocols, the research framework suggests intermittent higher-dose timing is more aligned with the mechanism of action than daily low-dose use.

Comparing Protocol Designs

The dose level and frequency trade off against each other. Higher-dose intermittent protocols have stronger research alignment. Lower-dose daily protocols offer simpler compliance but less mechanistic grounding. Bioavailability technology, like liposomal delivery and enhanced-absorption forms, partially bridges this gap by improving absorption at lower absolute doses.

How Often to Pulse: Matching Frequency to Age

Senescent cell burden rises with age, and the body's ability to clear these cells declines over time. A reasonable frequency framework scales the number of monthly pulses to age:

Each pulse runs across two consecutive days. This is general guidance based on aging biology, not a clinical prescription, so choose a cadence with your health goals and physician in mind.

Why Bioavailability Engineering Matters for Senolytic Dosing

This is often overlooked but significant: senolytic compounds are notoriously poorly absorbed. Fisetin, the most-studied natural senolytic, has low oral bioavailability in its standard form, and only a small fraction of an oral dose reaches the bloodstream unchanged.

TimeWarp's Monthly Pulse uses three approaches to address this:

Liposomal delivery: Liposomal encapsulation protects fisetin from degradation and improves cell uptake. In preclinical work, liposomal fisetin reached up to a 47-fold increase in relative bioavailability compared to free fisetin (Touil et al., 2013).

Isoquercetin instead of quercetin: Isoquercetin (quercetin-3-O-glucoside) is absorbed via active transport through SGLT1 transporters in the intestine, a more efficient route than the passive diffusion standard quercetin relies on. This generally results in more efficient absorption than equivalent quercetin doses.

Piperine as a bioenhancer: Piperine, from black pepper, can improve the absorption of various plant compounds, including flavonoids, by slowing their metabolism.

The combination means a 300mg liposomal fisetin dose per day across the two-day pulse (600mg per pulse), paired with co-administered bioavailability compounds, aims to achieve plasma and tissue levels comparable to higher doses of unengineered fisetin. Put another way, that 600mg liposomal pulse should not be read, milligram for milligram, as a low dose next to the higher standard-fisetin amounts used in research protocols. The absorbed fraction, not the label number, is what reaches your tissues.

One caveat: Enhanced bioavailability does not automatically establish clinical equivalence to higher unengineered doses. Dose-response curves aren't always linear. Achieving similar or better tissue concentrations with lower absolute doses is mechanistically sound, but it remains a formulation strategy, not a proven clinical equivalence.

Design Implications: How to Evaluate Senolytic Supplements

If you're comparing senolytic supplement protocols, three design principles matter:

1. Intermittent timing over daily dosing. Research supports concentrated, spaced dosing aligned with the hit-and-run clearance mechanism rather than continuous daily exposure.
2. Bioavailability technology as a dose strategy. Enhanced-absorption forms can deliver more effective dosing at lower absolute quantities.
3. Clarity about human evidence limits. Human senolytic efficacy data is preclinical and early-stage. Protocol choices reflect mechanistic rationale, not proven clinical superiority.

The best senolytic protocol isn't necessarily the highest-dose one. It's the one most aligned with how the compounds actually work: concentrated exposure, adequate tissue bioavailability, and recovery periods for cellular clearance.

Frequently Asked Questions

What are senolytics?

Senolytics are compounds being studied for their potential to trigger death in senescent cells, the aging cells (often called "zombie cells") that stop dividing but emit inflammatory signals. The term means "senescent-cell-breaking." Fisetin, quercetin, and dasatinib plus quercetin combinations are the most studied examples. Research suggests they work through intermittent "hit-and-run" dosing rather than daily chronic use. Most senolytic research is preclinical; human efficacy data remains limited to early-stage trials.

Do senolytic supplements actually work?

This depends on the evidence standard. Preclinical research in animal models and cell culture is strong: senolytic compounds reliably reduce senescence markers in multiple tissues and improve various aging-related measures in older mice. Human clinical evidence is minimal. No Phase 3 trials have established senolytic efficacy in aging populations, and small human trials are ongoing without published results. The mechanism appears real. Whether senolytic supplements improve human aging outcomes, and at what dose and timing, remains an open question. This is why appropriate framing is "supports the body's natural cellular maintenance processes" rather than "clears senescent cells."

Should I take fisetin daily or monthly?

Research supports the monthly, intermittent approach over daily chronic dosing. Preclinical studies show intermittent fisetin reduced senescence markers across multiple tissues, consistent with a hit-and-run mechanism, where senescent cells are cleared acutely and ongoing dosing provides limited additional benefit. Continuous daily low-dose exposure lacks mechanistic support. Mayo Clinic research protocols use high-dose intermittent approaches (roughly 1400mg for 2 days, repeated every 1 to 2 months). Community protocols typically follow 500 to 1000mg monthly. Lower-dose daily protocols favor compliance simplicity over mechanistic alignment.

What is a senolytic pulse protocol?

A pulse protocol delivers a concentrated dose of senolytic compounds, then pauses for several weeks to allow senescent cell clearance and cellular recovery. The research basis comes from preclinical studies showing senolytics work via acute senescent cell removal: once cleared, the target population is reduced and continued dosing adds little. TimeWarp's Monthly Pulse follows this design: 300mg liposomal fisetin and 150mg isoquercetin each day across two consecutive days, delivering 600mg fisetin per monthly pulse. The two-day timing mirrors the institutional research protocols, while the liposomal delivery and isoquercetin help the lower absolute dose work harder.

What's the difference between quercetin and isoquercetin?

Isoquercetin (quercetin-3-O-glucoside) is a naturally occurring form of quercetin that's more bioavailable. It's absorbed via active transport through SGLT1 transporters in the intestine, a more efficient route, while standard quercetin relies on slower passive diffusion. For senolytic formulations, isoquercetin is the stronger choice from a bioavailability standpoint. IM8's daily formula includes 250mg quercetin; TimeWarp uses 150mg isoquercetin per day across a two-day monthly pulse (300mg per pulse). The bioavailability advantage means the effective delivery per pulse may be comparable despite the lower absolute dose.

How does liposomal fisetin improve absorption?

Liposomal encapsulation protects fisetin from degradation in the digestive tract and improves cell membrane penetration. Preclinical research shows liposomal fisetin reached up to 47-fold higher relative bioavailability than free fisetin (Touil et al., 2013). This allows lower absolute doses to reach meaningful plasma and tissue concentrations, which is particularly important for senolytic compounds that naturally have poor oral bioavailability.

Is fisetin safe at high doses?

Limited human safety data exists because senolytic trials are early-stage. Preclinical studies show fisetin is well-tolerated at high intermittent doses in animals. Mayo-affiliated trials using 20mg/kg (about 1400mg) are evaluating safety in humans, with results not yet published. Individual safety depends on medications, health status, and personal tolerance, so consult a healthcare provider before starting any senolytic supplement.

Key Takeaways

• Senescent cells accumulate with age and emit inflammatory signals. Senolytics are compounds being studied to support the body's natural cellular maintenance processes in managing these cells.
• Research suggests senolytics work through a "hit-and-run" mechanism: concentrated, intermittent dosing rather than daily chronic low-dose exposure.
• Human senolytic efficacy data remains preclinical and early-stage. No Phase 3 trials in aging populations exist yet.
• Institutional research protocols use roughly 1400mg fisetin (20mg/kg) for 2 consecutive days, repeated every 1 to 2 months. This is the strongest human-referenced approach.
• Intermittent pulse dosing is more research-aligned than daily dosing. TimeWarp's Monthly Pulse is designed around this intermittent mechanism, taken across two consecutive days each month.
• Bioavailability engineering (liposomal delivery, isoquercetin, piperine) lets lower absolute doses reach meaningful tissue concentrations.
• When evaluating senolytic supplements, weigh timing (intermittent beats daily), bioavailability technology, and clear evidence framing.

About the Author

Dr. Vittorio Sebastiano is Professor of Biological Chemistry at UC Irvine and Adjunct Professor of Obstetrics and Gynecology at Stanford University School of Medicine. He is internationally recognized for pioneering Epigenetic Reprogramming of Aging (ERA), a technology that rejuvenates adult cells while preserving their identity. He has authored more than 50 peer-reviewed publications in Nature, Science, Cell, Nature Biotechnology, and Nature Aging, received the Breakthrough in Gerontology Award and the AFAR Junior Investigator Award, and serves as Associate Editor for Rejuvenation Research.

References

• Yousefzadeh MJ, et al. "Fisetin is a senotherapeutic that extends health and lifespan." EBioMedicine, 2018.
• Hickson LJ, et al. "Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease." EBioMedicine, 2019; 47:446-456. DOI 10.1016/j.ebiom.2019.08.069.
• Justice JN, et al. "Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study." EBioMedicine, 2019; 40:554-563.
• Mahoney SA, et al. "Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence." Aging Cell, 2024; 23(3):e14060.
• Murray KO, et al. "Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging: a comparison to genetic clearance of senescent cells and synthetic senolytic approaches." Aging Cell, 2025; 24(8):e70114. DOI 10.1111/acel.70114.
• Touil YS, et al. "Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy." International Journal of Pharmaceutics, 2013. DOI 10.1016/j.ijpharm.2013.01.050. Reported up to a 47-fold increase in relative bioavailability versus free fisetin in mice.
• AFFIRM trial, Mayo Clinic: NCT03430037. COVID-FIS pilot: NCT04537299. STOP-Sepsis: NCT05758246. Fisetin vascular function trial, University of Colorado Boulder: NCT06133634.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any new supplement regimen.